Skip to main content

Translate Bio, Inc. (TBIO)

Sep 14, 2021 - TBIO was delisted (reason: acquired by Sanofi)
37.98
+0.62 (1.66%)
Pre-market:Sep 14, 2021 8:00 AM EDT
37.36
0.00 (0.00%)
At close: Sep 13, 12:00 AM
Market Cap2.82B
Revenue (ttm)225.09M
Net Income (ttm)40.45M
Shares Out75.25M
EPS (ttm)0.53
PE Ratio70.62
Forward PE29.67
Dividendn/a
Ex-Dividend Daten/a
Volume-
Open-
Previous Close37.36
Day's Range37.16 - 37.64
52-Week Range11.91 - 37.99
Beta0.97
AnalystsHold
Price Target32.57 (-12.8%)
Est. Earnings DateNov 4, 2021

About TBIO

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was ...

IndustryBiotechnology
IPO DateJun 28, 2018
Employees122
Stock ExchangeNASDAQ
Ticker SymbolTBIO
Full Company Profile

Financial Performance

In 2020, Translate Bio's revenue was $138.81 million, an increase of 1,678.72% compared to the previous year's $7.80 million. Losses were -$53.79 million, -52.52% less than in 2019.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Translate Bio stock is "Hold." The 12-month stock price forecast is 32.57, which is a decrease of -12.82% from the latest price.

Price Target
$32.57
(-12.82% downside)
Analyst Consensus: Hold

News

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

Other symbols:SNY
1 month ago - GlobeNewsWire

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicin...

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Reminds PFOH, TBIO, LDL, and SNR Shareholders About Its Ongoing Investigations

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...

Other symbols:LDL
1 month ago - PRNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Translate Bio, Inc. - TBIO

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action...

2 months ago - PRNewsWire

Inside Sanofi's $3.2B Translate Bio Buyout

Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the company,...

Other symbols:SNY
2 months ago - Benzinga

Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary  conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA t...

2 months ago - GlobeNewsWire

TRANSLATE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequac...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Translate Bio (Nas...

Other symbols:SNY
2 months ago - Business Wire

Delta Variant Surge Brings Biotech ETFs in Focus

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

2 months ago - Zacks Investment Research

Why Translate Bio Stock Soared Today

The biotech is being bought for $3.2 billion.

2 months ago - The Motley Fool

SHAREHOLDER ALERT: WeissLaw LLP Investigates Translate Bio, Inc.

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Translate Bio, Inc. ("Translate" or the ...

Other symbols:SNY
2 months ago - PRNewsWire

Shareholder Alert: Ademi LLP investigates whether Translate Bio, Inc. has obtained a Fair Price in its transaction wi...

MILWAUKEE, Aug. 3, 2021 /PRNewswire/ -- Ademi LLP is investigating Translate Bio (NASDAQ: TBIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click ...

2 months ago - PRNewsWire

Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio

Biotech stocks surge after big news & bullish analyst ratings. The post Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio appeared first on Penny Stocks to Buy, Picks, News and Inf...

Other symbols:SNY
2 months ago - PennyStocks

Translate Bio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Translate Bio, ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Translate Bio, Inc. (NASDAQ: TBIO) to Sanofi for $38.00 per share in cash is fair to ...

2 months ago - Business Wire

Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights

A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion bu...

Other symbols:SNY
2 months ago - Benzinga

Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA Tech

Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.

Other symbols:SNY
2 months ago - Forbes

Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio

French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Other symbols:SNY
2 months ago - Reuters

Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development

Sanofi to acquire Translate Bio ; a dvance s deployment of mRNA technology across vaccines and therapeutics development

2 months ago - GlobeNewsWire

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development

-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi's recently announced  mRNA Center of...

2 months ago - GlobeNewsWire

Exclusive-Sanofi offers to buy U.S. mRNA partner Translate Bio -sources

PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology aft...

Other symbols:SNY
2 months ago - Reuters

Will Translate Bio, Inc. (TBIO) Report Negative Q2 Earnings? What You Should Know

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Why Translate Bio Shares Are Trading Higher Today

Translate Bio (NASDAQ:TBIO) shares are trading 9.5% higher after Roth Capital Partners raised its price target on the stock from $28 to $45. Roth Capital Partners in a Sunday research report noted the c...

2 months ago - Benzinga

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicine...

3 months ago - GlobeNewsWire

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Other symbols:SNY
3 months ago - Zacks Investment Research

Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. T...

Other symbols:SNY
3 months ago - Benzinga

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data fo...

3 months ago - GlobeNewsWire